EVI joining CEPI-funded programme for development of broadly protective betacoronaviruses vaccines
We are delighted to announce that CEPI, the Coalition for Epidemic Preparedness Innovations has awarded US$200m to advance the development of vaccines that provide broad protection against betacoronaviruses that already pose a significant epidemic or pandemic risk, such as SARS-CoV, SARS-CoV-2 & MERS-CoV.
This project aims to establish preclinical proof of concept for a vaccine based on mRNA technology that protects against a wide variety of betacoronaviruses, NEC, through NEC OncoImmunity, a Norwegian branch of NEC that specializes in artificial intelligence-driven biotechnology, will lead a research consortium in co-operation with the European Vaccine Initiative (EVI) and Oslo University Hospital. The success of this innovative approach will pave the way for future research on developing vaccines against other pathogens.
We are very happy to be able to cooperate CEPI who is committed to the principle of equitable access to the vaccines it funds and with their support we will strengthen our research in vaccine development.
Read more: https://100days.cepi.net/cepi-japans-nec-broadly-protective-ai-betacoronavirus-vaccine/